Tumor-derived exosomes (TEXs) have been considered as a new kind of cancer vaccine, but the antitumor effects are not satisfactory. In order to improve the efficacy of TEXs, we investigated whether exosomes derived from glycosyl-phosphatidylinositol-anchored interleukin 2 (GPI-IL-2) gene-modified bladder cancer cells can increase the antitumor effects.
Methods and study design
We transfected melanoma antigen-1 (MAGE-1)-expressing T24 tumor cells with a plasmid encoding GPI-IL-2 and prepared the TEXs. Exosomes expressing GPI-IL-2 were characterized by electron microscope and Western blot analysis.
Results
IL-2 was present on the cell surface in the GPI-anchored form as demonstrated by fluorescent microscope and ELISA analyses. Exosomes expressing GPI-IL-2 naturally contained bioactive GPI-IL-2 and tumor-associated antigen MAGE-1. Moreover, exosomes expressing GPI-IL-2-pulsed dendritic cells could induce the proliferation of T cells and the antigen-specific cytotoxic T-lymphocyte immune response more efficiently.
Conclusions
GPI-IL-2 gene-modified tumor cells can make the TEXs contain GPI-IL-2, resulting in increased antitumor effects. Our study provided a feasible approach for exosome-based tumor immunotherapy.
WolfersJ., LozierA., RaposoG., RegnaultA., ThéryC., MasurierC., FlamentC., PouzieuxS., FaureF., TurszT., AngevinE., AmigorenaS., ZitvogelL.: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross priming. Nat Med, 7: 297–303, 2001.
2.
McLellanA.D.: Exosome release by primary B cells. Crit Rev Immunol, 29: 203–217, 2009.
3.
TheryC., DubanL., SeguraE., VéronP., LantzO., AmigorenaS.: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol, 3: 1156–1162, 2002.
4.
DenzerK., KleijmeerM.J., HeijnenH.F., StoorvogelW., GeuzeH.J.: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci, 19: 3365–3374, 2000.
LotemM., ShiloniE., PappoI., DrizeO., HamburgerT., WeitzenR., IsacsonR., KaduriL., MerimsS., FrankenburgS., PeretzT.: Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer, 90: 773–780, 2004.
10.
NguyenC.L., SalemM.L., RubinsteinM.P., DemchevaM., VournakisJ.N., ColeD.J., GillandersW.E.: Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine, 21: 2318–2328, 2003.
11.
LiY.G., WangZ.P., TianJ.Q., TianB.Q., RodriguesR., ShangP.F., ZhangT.: Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cells in vitro. Cancer Invest, 27: 909–917, 2009.
BumgarnerG.W., ShashidharamurthyR., NagarajanS., D'SouzaM.J., SelvarajP.: Surface engineering of microparticles by novel protein transfer for targeted antigen/drug delivery. J Control Release, 137: 90–97, 2009.
14.
KuengH.J., LebV.M., HaidererD., RaposoG., TheryC., DerdakS.V., SchmettererK.G., NeunkirchnerA., SillaberC., SeedB., PicklW.F.: General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol, 81: 8666–8676, 2007
15.
NagarajanS., SelvarajP.: Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine, 24: 2264–2274, 2006
16.
JiJ., LiJ., HolmesL.M., BurginK.E., YuX., WagnerT.E., WeiY.: Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma tumor growth in mice. Mol Cancer Ther, 1: 1019–1024, 2002.
17.
GastparR., GehrmannM., BauseroM.A., AseaA., GrossC., SchroederJ.A., MulthoffG.: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res, 65: 5238–5247, 2005.
EscudierB., DorvalT., ChaputN., AndréF., CabyM.P., NovaultS., FlamentC., LeboulaireC., BorgC., AmigorenaS., BoccaccioC., BonnerotC., DhellinO., MovassaghM., PipernoS., RobertC., SerraV., ValenteN., Le PecqJ.B., SpatzA., LantzO., TurszT., AngevinE., ZitvogelL.: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med, 3: 10, 2005.
20.
MorseM.A., GarstJ., OsadaT., KhanS., HobeikaA., ClayT.M., ValenteN., ShreeniwasR., SuttonM.A., DelcayreA., HsuD.H., Le PecqJ.B., LyerlyH.K.: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med, 3: 9, 2005.
21.
AndréF., SchartzN.E., ChaputN., FlamentC., RaposoG., AmigorenaS., AngevinE., ZitvogelL.: Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine, 20: A28–31, 2002.
22.
ChoJ.A., YeoD.J., SonH.Y., KimH.W., JungD.S., KoJ.K., KohJ.S., KimY.N., KimC.W.: Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer, 114: 613–622, 2005.
23.
XieY., BaiO., ZhangH., YuanJ., ZongS., ChibbarR., SlatteryK., QureshiM., WeiY., DengY., XiangJ.: Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumor immunity than exosomes released from heat-shocked tumor cells expressing cytoplasmic HSP70. J Cell Mol Med, 2009; Jul 20 [Epub ahead of print].
24.
JungbluthA.A., BusamK.J., KolbD., IversenK., CoplanK., ChenY.T., SpagnoliG.C., OldL.J.: Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer, 85: 460–465, 2000.
25.
PatardJ.J., BrasseurF., Gil-DiezS., RadvanyiF., MarchandM., FrançoisP., Abi-AadA., Van CanghP., AbbouC.C., ChopinD.: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer, 64: 60–64, 1995.
26.
NishiyamaT., TachibanaM., HoriguchiY., NakamuraK., IkedaY., TakesakoK., MuraiM.: Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res, 7: 23–31, 2001.
27.
AkiyamaY., MaruyamaK., TaiS., KomiyamaM., IizukaA., TakikawaM., OhshitaC., YamamotoA., YamazakiN., KiyoharaY., YamaguchiK.: Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient. Anticancer Res, 29: 647–655, 2009.
28.
AndréF., ChaputN., SchartzN.E., FlamentC., AubertN., BernardJ., LemonnierF., RaposoG., EscudierB., HsuD.H., TurszT., AmigorenaS., AngevinE., ZitvogelL.: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol, 172: 2126–2136, 2004.
29.
MorelliA.E., LarreginaA.T., ShufeskyW.J., SullivanM.L., StolzD.B., PapworthG.D., ZahorchakA.F., LogarA.J., WangZ., WatkinsS.C., FaloL.D.Jr., ThomsonA.W.: Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood, 104: 3257–3266, 2004.
30.
ThéryC., RegnaultA., GarinJ., WolfersJ., ZitvogelL., Ricciardi-CastagnoliP., RaposoG., AmigorenaS.: Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. JCell Biol, 147: 599–610, 1999.
31.
KüngM., StadelmannB., BrodbeckU., BütikoferP.: Addition of G418 and other aminoglycoside antibiotics to mammalian cells results in the release of GPI-anchored proteins. FEBS Lett, 409: 333–338, 1997.
32.
DaiS., ZhouX., WangB., WangQ., FuY., ChenT., WanT., YuY., CaoX.: Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med, 84: 1067–1076, 2006.
33.
OverwijkW.W., TheoretM.R., RestifoN.P.: The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am, 6: 76–80, 2000.
34.
FukaoT., KoyasuS.: Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur J Immunol, 30: 1453–1457, 2000.
